Vericiguat improves cardiac function and microcirculation of a male patient with Fabry disease: A case report.
Bingyang ZhouNing RenJie GengPublished in: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (2024)
Fabry disease (FD) is a rare X chromosome-linked disorder and can be easily misdiagnosed. Here, we report the case of a 69-year-old male patient with FD who developed heart failure and showed extremely high pulmonary artery pressure. His initial symptom was recurrent atrial fibrillation. The left and right atrial inner diameters were large, and the ventricular wall was thick. Gene analysis which showed GLA c.215T>C p.Met72Thr mutation and single photon emission computed tomography indicated the diagnosis of FD with coronary microvascular dysfunction. The patient was prescribed anti-heart failure drugs, including vericiguat. Following the treatment, his heart function and microvascular perfusion significantly improved, which might be due to the beneficial effects of vericiguat.
Keyphrases
- heart failure
- atrial fibrillation
- pulmonary artery
- coronary artery
- computed tomography
- case report
- catheter ablation
- left ventricular
- pulmonary hypertension
- pulmonary arterial hypertension
- replacement therapy
- copy number
- left atrial
- magnetic resonance imaging
- oral anticoagulants
- cardiac resynchronization therapy
- gene expression
- oxidative stress
- acute heart failure
- percutaneous coronary intervention
- contrast enhanced
- tyrosine kinase
- aortic stenosis
- left atrial appendage
- image quality
- combination therapy
- aortic valve
- solid state
- smoking cessation